Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Calquence is a prescription kinase inhibitor containing acalabrutinib. It is approved for selected adults with mantle cell lymphoma and for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Current formulations include 100 mg capsules and tablets. Calquence is generally taken about every 12 hours until disease progression or unacceptable toxicity.
read more about calquence ...Acalabrutinib forms a covalent bond with Bruton tyrosine kinase and inhibits its activity. BTK is part of B-cell receptor and cytokine receptor signaling pathways involved in B-cell proliferation, trafficking, chemotaxis, and adhesion. Blocking BTK reduces signaling that contributes to growth and survival of malignant B cells.
Calquence treats adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. It also treats mantle cell lymphoma after at least one prior therapy. In previously untreated mantle cell lymphoma, Calquence is used with bendamustine and rituximab in adults who are ineligible for autologous hematopoietic stem cell transplantation.
The recommended Calquence dose is 100 mg by mouth approximately every 12 hours. It is taken with or without food. Capsules are swallowed whole with water and should not be opened, broken, or chewed. Dose interruption, reduction, or discontinuation is used for selected adverse reactions and drug interactions.
Serious risks include severe or opportunistic infections, hemorrhage, low blood cell counts, second primary cancers, cardiac arrhythmias, and liver injury. Complete blood counts and liver function require monitoring during treatment. Strong CYP3A inhibitors or inducers can change acalabrutinib exposure, and severe liver impairment is a reason to avoid treatment.
Yes. Acalabrutinib inhibits Bruton tyrosine kinase, a signaling protein involved in B-cell growth and survival.
The recommended dose is 100 mg approximately every 12 hours.
Calquence treats selected mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma in adults.
No. Current capsule labeling directs patients to swallow the capsules whole with water.
Acalabrutinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a618004.html. Date Accessed September 21, 2026.
Acalabrutinib Maleate Monohydrate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/acalabrutinib. Date Accessed September 21, 2026.
CALQUENCE (acalabrutinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216387s006lbl.pdf. Date Accessed September 21, 2026.
DailyMed - CALQUENCE (acalabrutinib) capsule, gelatin coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd4835ef-e1bc-4997-a399-1ffa2556fbfe. Date Accessed September 21, 2026.
DailyMed - CALQUENCE (acalabrutinib) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1409184-3267-4d8c-8f17-4e01f69828b1. Date Accessed September 21, 2026.